REGENERON PHARMACEUTICALS, INC. Fair Value of Long-Term Debt
REGENERON PHARMACEUTICALS, INC. (REGN) had Fair Value of Long-Term Debt of $1.48 billion as of 2023-06-30, per its 10-Q filed 2023-08-03.
Discontinued › Notes › Debt Instruments
us-gaap:LongTermDebtFairValue · last filed 2023-08-03
- 2023-06-30: Long-term Debt, Fair Value $1.48B.
- 2023-03-31: Long-term Debt, Fair Value $1.52B.
- 2022-12-31: Long-term Debt, Fair Value $1.44B.
- 2022-09-30: Long-term Debt, Fair Value $1.40B.
| Period end | Long-term Debt, Fair Value |
|---|---|
| 2023-06-30 | $1.48B 10-Q · filed 2023-08-03 |
| 2023-03-31 | $1.52B 10-Q · filed 2023-05-04 |
| 2022-12-31 | $1.44B 10-Q · filed 2023-08-03 |
| 2022-09-30 | $1.40B 10-Q · filed 2022-11-03 |
| 2022-06-30 | $1.51B 10-Q · filed 2022-08-03 |
| 2022-03-31 | $1.69B 10-Q · filed 2022-05-04 |
| 2021-12-31 | $1.89B 10-K · filed 2023-02-06 |
| 2021-09-30 | $1.89B 10-Q · filed 2021-11-04 |
| 2021-06-30 | $1.87B 10-Q · filed 2021-08-05 |
| 2021-03-31 | $1.80B 10-Q · filed 2021-05-06 |
| 2020-12-31 | $1.96B 10-K · filed 2022-02-07 |
| 2020-09-30 | $1.93B 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |